Skip to main content
Top
Published in: Endocrine Pathology 3/2012

01-09-2012

Correlation Between Histological Subtypes and MRI Findings in Clinically Nonfunctioning Pituitary Adenomas

Authors: Hiroshi Nishioka, Naoko Inoshita, Toshiaki Sano, Noriaki Fukuhara, Shozo Yamada

Published in: Endocrine Pathology | Issue 3/2012

Login to get access

Abstract

Clinically nonfunctioning pituitary adenomas (CNFPAs) consist of several histological subtypes, including null cell adenoma (NCA), silent gonadotroph cell adenoma (SGA), silent corticotroph adenoma (SCA), and other silent adenomas (OSA) (i.e., GH, TSH, and prolactin adenomas). To detect possible correlations between MRI findings and the subtypes, we retrospectively studied 390 consecutive patients with CNFPA who underwent surgery between 2008 and 2010. They were classified into three groups: NCA/SGA (313 cases), SCA (39 cases), and OSA (36 cases); in addition there were two unusual cases of plurihormonal adenoma. Three MRI findings were less common in NCA/SGA than in the other groups (P < 0.0001): giant adenoma (>40 mm), marked cavernous sinus invasion (Knosp grade 4), and lobulated configuration of the suprasellar tumor. When these MRI findings were negative in patients older than 40 years old, 91.0 % (212/233) were NCA/SGA. These MRI findings were frequently noted despite a low MIB-1 index in SCA. OSA showed a high MIB-1 index and a preponderance in younger patients. In conclusion, although SCA and OSA consisted of only 20 % of CNFPAs, their frequency significantly increased when the tumor was large, invasive, and lobulated, and the patient was younger than 40 years old.
Literature
1.
go back to reference Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of silent corticotroph pituitary adenomas. Br J Neurosurg 19: 38–42, 2005PubMedCrossRef Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of silent corticotroph pituitary adenomas. Br J Neurosurg 19: 38–42, 2005PubMedCrossRef
2.
go back to reference Bradley KJ, Wass JAH, Turner H. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol 58: 59–64, 2003CrossRef Bradley KJ, Wass JAH, Turner H. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol 58: 59–64, 2003CrossRef
3.
go back to reference Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young Jr WF. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo clinic experience. Clin Endocrinol 71: 92–99, 2009CrossRef Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young Jr WF. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo clinic experience. Clin Endocrinol 71: 92–99, 2009CrossRef
4.
go back to reference Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary–immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29: 511–524, 2005PubMedCrossRef Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary–immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29: 511–524, 2005PubMedCrossRef
5.
go back to reference Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res 71: 123–130, 2009PubMedCrossRef Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res 71: 123–130, 2009PubMedCrossRef
6.
go back to reference Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws Jr ER, Young Jr WF. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47: 723–730, 2000PubMed Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws Jr ER, Young Jr WF. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47: 723–730, 2000PubMed
7.
go back to reference Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws Jr ER. Clinical characteristics of silent corticotroph adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53: 1076–1085, 2003PubMedCrossRef Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws Jr ER. Clinical characteristics of silent corticotroph adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53: 1076–1085, 2003PubMedCrossRef
8.
go back to reference Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61: 580–585, 2007PubMedCrossRef Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61: 580–585, 2007PubMedCrossRef
9.
go back to reference Nishioka H, Hara T, Usui M, Fukuhara N, Yamada S. Simultaneous combined supra-infrasellar approach for giant/large multi-lobulated pituitary adenomas. World Neurosurg 2011 Nov 7. doi:10.1016/j.wneu.2011.07.013 Nishioka H, Hara T, Usui M, Fukuhara N, Yamada S. Simultaneous combined supra-infrasellar approach for giant/large multi-lobulated pituitary adenomas. World Neurosurg 2011 Nov 7. doi:10.​1016/​j.​wneu.​2011.​07.​013
10.
go back to reference Zada G, Du R, Laws ER Jr. Defining the “edge of the envelope”: patient selection in treating complex sellar-based neoplasms via transsphenoidal versus open craniotomy. J Neurosurg 114: 286–300, 2011PubMedCrossRef Zada G, Du R, Laws ER Jr. Defining the “edge of the envelope”: patient selection in treating complex sellar-based neoplasms via transsphenoidal versus open craniotomy. J Neurosurg 114: 286–300, 2011PubMedCrossRef
11.
go back to reference Chako G, Chako AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13: 337–344, 2010CrossRef Chako G, Chako AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13: 337–344, 2010CrossRef
12.
go back to reference Chako G, Chako AG, Lombardero M, Mani S, Seshadri MS, Kovacs K, Scheithauer BW. Clinicopathological correlates of giant adenomas. J Clin Neurosci 16: 660–665, 2009CrossRef Chako G, Chako AG, Lombardero M, Mani S, Seshadri MS, Kovacs K, Scheithauer BW. Clinicopathological correlates of giant adenomas. J Clin Neurosci 16: 660–665, 2009CrossRef
13.
go back to reference Madsen H, Borges TM, Knox AJ, Michaellis KA, Xu M, Lillehei KO, Wierman ME, Kleinschmidt-Demasters BK. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. Am J Surg Pathol 35: 1204–1213, 2011PubMedCrossRef Madsen H, Borges TM, Knox AJ, Michaellis KA, Xu M, Lillehei KO, Wierman ME, Kleinschmidt-Demasters BK. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. Am J Surg Pathol 35: 1204–1213, 2011PubMedCrossRef
14.
go back to reference Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12, 2001PubMedCrossRef Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12, 2001PubMedCrossRef
15.
go back to reference Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74: 71–76, 2005PubMedCrossRef Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74: 71–76, 2005PubMedCrossRef
16.
go back to reference Knosp E, Steiner E, Kitz K, Matla C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 35: 542–544, 1994CrossRef Knosp E, Steiner E, Kitz K, Matla C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 35: 542–544, 1994CrossRef
17.
go back to reference Young Jr WF, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 71: 649–656, 1996PubMedCrossRef Young Jr WF, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 71: 649–656, 1996PubMedCrossRef
18.
go back to reference Yoneda A, Sano T, Yamada S, Obari A, Qian ZR, Wang EL, Inoshita N, Kudo E. Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. Endocr Pathol 21: 40–47, 2010PubMedCrossRef Yoneda A, Sano T, Yamada S, Obari A, Qian ZR, Wang EL, Inoshita N, Kudo E. Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. Endocr Pathol 21: 40–47, 2010PubMedCrossRef
19.
go back to reference Wang EL, Qian ZR, Yamada S, Rahman MdM, Inoshita N, Kageji T, Endo H, Kudo E, Sano T. Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20: 209–220, 2009PubMedCrossRef Wang EL, Qian ZR, Yamada S, Rahman MdM, Inoshita N, Kageji T, Endo H, Kudo E, Sano T. Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20: 209–220, 2009PubMedCrossRef
20.
go back to reference Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu J. Are nonfunctioning pituitary adenomas extending to the cavernous sinus aggressive and/or invasive? Neurosurgery 49: 857–862, 2001PubMed Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu J. Are nonfunctioning pituitary adenomas extending to the cavernous sinus aggressive and/or invasive? Neurosurgery 49: 857–862, 2001PubMed
21.
go back to reference Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional adenomas. J Neurosurg 108: 736–745, 2008PubMedCrossRef Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional adenomas. J Neurosurg 108: 736–745, 2008PubMedCrossRef
22.
go back to reference Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108: 525–532, 2008PubMedCrossRef Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108: 525–532, 2008PubMedCrossRef
23.
go back to reference Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, Tsien C. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55: 100–107, 2004PubMedCrossRef Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, Tsien C. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55: 100–107, 2004PubMedCrossRef
24.
go back to reference Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patients age, and MIB-1 index. J Neurosurg 98: 359–365, 2003PubMedCrossRef Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patients age, and MIB-1 index. J Neurosurg 98: 359–365, 2003PubMedCrossRef
Metadata
Title
Correlation Between Histological Subtypes and MRI Findings in Clinically Nonfunctioning Pituitary Adenomas
Authors
Hiroshi Nishioka
Naoko Inoshita
Toshiaki Sano
Noriaki Fukuhara
Shozo Yamada
Publication date
01-09-2012
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2012
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9208-9

Other articles of this Issue 3/2012

Endocrine Pathology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.